Article

Urology Times, Digital Edition, November 2010

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Andrea Pezzella, MD, URPS, FACOG, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Related Content
Experts urge FDA to remove black box warning on low-dose vaginal estrogen
July 18th 2025

Experts urge FDA to remove black box warning on low-dose vaginal estrogen

Hannah Clarke
In a panel meeting convened by the FDA, experts urged the agency to revise or remove the outdated boxed warning on hormone therapies for menopause.
Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD
July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD
Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.
Urology in focus: Key moments from 2025
July 18th 2025

Urology in focus: Key moments from 2025

Hannah Clarke
Take a look back through some of the top stories from the first half of the year.
Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD
June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD
Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.
FDA, French ANSM greenlight pivotal trial of UroActive smart implant for male SUI
July 17th 2025

FDA, French ANSM greenlight pivotal trial of UroActive smart implant for male SUI

Hannah Clarke Jason M. Broderick
The SOPHIA2 trial will assess the safety and efficacy of the UroActive implant in men with SUI.
FDA grants priority review to NDA for TAR-200 in BCG-unresponsive NMIBC
July 17th 2025

FDA grants priority review to NDA for TAR-200 in BCG-unresponsive NMIBC

Hannah Clarke
The new drug application for TAR-200 is supported by data from cohort 2 of the phase 2b SunRISe-1 trial.
© 2025 MJH Life Sciences

All rights reserved.